Law 360 M&A

MARCH 21, 2024

A shareholder of liver disease-focused biopharmaceutical company CymaBay Therapeutics Inc. sued the company in Delaware Chancery Court to extract more information over a proposed $4.3 billion merger with Gilead Sciences Inc.,

52

52

Law 360 M&A

FEBRUARY 12, 2024

Gilead Sciences Inc. said Monday that it has agreed to purchase liver disease-focused clinical-stage biopharmaceutical company CymaBay Therapeutics Inc. billion in cash.

52

52

Benzinga

SEPTEMBER 21, 2023

Applied Molecular Transport Inc (NASDAQ: AMTI ) has agreed to merge with Cyclo Therapeutics Inc (NASDAQ: CYTH ) in an all-stock transaction. Following the merger's closing, the combined company will operate under Cyclo Therapeutics and continue trading on The Nasdaq Capital Market under the CYTH ticker.

Marketability 52

Marketability 52

Benzinga

APRIL 4, 2022

April 04, 2022 (GLOBE NEWSWIRE) -- Scilex Holding Company ("Scilex"), a nearly 100% (or over 99.9%) majority-owned subsidiary of Sorrento Therapeutics, Inc. Scilex Holding Company and Vickers Vantage Corp. About Scilex Holding Company. About Sorrento Therapeutics, Inc. PALO ALTO, Calif.,

Marketability 40

Marketability 40

Benzinga

FEBRUARY 23, 2023

Redx Pharma and Jounce Therapeutics Inc (NASDAQ: JNCE ) agreed to merge via a proposed all-share transaction. Redx is a clinical-stage biotechnology company focused on discovering and developing small molecule, targeted therapeutics for cancer and fibrotic diseases and cancer-associated fibrosis.

98

98

Benzinga

JANUARY 2, 2024

02, 2024 (GLOBE NEWSWIRE) -- Tome Biosciences, Inc., the programmable genomic integration (PGI) company, today announces that it has acquired Replace Therapeutics Inc., a private biotechnology company developing a novel PGI method capable of inserting and deleting small DNA sequences. WATERTOWN, Mass.,

Technology 45

Technology 45

Benzinga

AUGUST 31, 2023

Zevra Therapeutics (NASDAQ: ZVRA ) has announced a merger with Acer Therapeutics (NASDAQ: ACER ) that is expected to be completed in Q4 of 2023. Under the terms of the agreement, Zevra Therapeutics has agreed to give Acer Therapeutics $15.00 million in stock in exchange for ACER stock.

52

52

Benzinga

APRIL 11, 2024

Janux Therapeutics Inc (NASDAQ: JANX ) shares are trading higher following Wednesday’s reports suggesting the company is considering a possible sale following interest from larger pharmaceutical firms.

52

52

Law 360 M&A

MARCH 12, 2024

The co-founder of Caraway Therapeutics Inc. sued in Delaware's Court of Chancery on Tuesday for an appraisal of his shares following the company's November merger with a subsidiary of pharmaceutical giant Merck, alleging that it "was an unfair cash-out transaction" and that he is owed at least a million more shares.

Appraisal 52

Appraisal 52

Benzinga

JULY 14, 2023

Korro Bio Inc and Frequency Therapeutics Inc (NASDAQ: FREQ ) announced an all- stock merger transaction. Under the merger agreement's terms, stockholders of Korro Bio will receive newly issued shares of Frequency Therapeutics. The combined company will focus on advancing Korro Bio's portfolio of.

52

52

Benzinga

OCTOBER 31, 2022

Post-closing company will be renamed "Scilex Holding Company" upon closing of the Business Combination, with common stock and warrants expected to trade on the Nasdaq Capital Market under the new ticker symbols "SCLX" and "SCLXW", respectively. majority-owned subsidiary of Sorrento Therapeutics, Inc.)

Marketability 40

Marketability 40

Benzinga

MARCH 7, 2023

F-Star Therapeutics Inc (NASDAQ: FSTX ) shares are trading higher Tuesday after the company announced clearance for the proposed acquisition by invoX Pharma. What To Know: The Committee on Foreign Investment in the United States (CFIUS) has cleared the previously announced acquisition by invoX Pharma, marking the final.

98

98

Benzinga

MAY 3, 2023

Magenta Therapeutics Inc (NASDAQ: MGTA ) and privately-held Dianthus Therapeutics Inc have announced to merge in an all-stock transaction. The combined company will focus on advancing Dianthus' pipeline of next-generation complement inhibitors, including DNTH103, currently in Phase 1 trial.

52

52

Benzinga

OCTOBER 14, 2022

Enliven Therapeutics Inc and Imara Inc (NASDAQ: IMRA ) agreed to merge in an all-stock transaction. The combined company will focus on advancing Enliven's pipeline of precision oncology product candidates. Enliven is advancing two parallel lead product candidates: ELVN-001 for chronic myeloid leukemia.

98

98

Law 360 M&A

DECEMBER 22, 2023

Covington & Burling LLP-advised Bristol Myers Squibb said Friday it has agreed to buy Boston-based biotechnology company Karuna Therapeutics Inc. for $14 billion, leading Karuna's stock to jump more than 47% in pre-market trading.

Marketability 52

Marketability 52

Benzinga

NOVEMBER 13, 2023

Selecta Biosciences Inc (NASDAQ: SELB ) and Cartesian Therapeutics Inc announced a reverse merger in an all-stock deal, with Selecta shareholders owning 26.9% of the new company.

Equity 59

Equity Marketability 59

Benzinga

APRIL 13, 2022

Antares Pharma Inc (NASDAQ: ATRS ) shares are trading higher Wednesday after the company announced it will be acquired by Halozyme Therapeutics Inc (NASDAQ: HALO ) for $5.60 per share in cash, valuing Antares at approximately $960 million. The transaction was unanimously approved by both.

98

98

Benzinga

JULY 18, 2023

Privately-held Neurogene Inc has agreed to merge with Neoleukin Therapeutics Inc (NASDAQ: NLTX ) in an all-stock transaction. The combined company will focus on advancing Neurogene's pipeline of genetic medicines, including NGN-401, a clinical-stage product for Rett syndrome.

52

52

Benzinga

MAY 1, 2024

Prioritization of Peak's ADC cancer therapeutic platform technology and Akari's PAS-nomacopan for Geographic Atrophy, a disabling ophthalmic disease Akari Therapeutics announces leadership changes in separate Akari press release BOSTON and PLEASANTON, Calif., Chairman, Akari Therapeutics.

Technology 40

Technology Alpha Equity Marketability 40

Law 360 M&A

APRIL 27, 2023

Drug-delivery firm Starton Therapeutics Inc. and special purpose acquisition company Healthwell Acquisition Corp. I agreed on Thursday to a merger that would take Starton public at an estimated $374 million value, guided by five law firms.

75

75

Benzinga

SEPTEMBER 12, 2023

Avalo Therapeutics Inc (NASDAQ: AVTX ) shares are trading higher after the company agreed to sell its rights, title, and interest in assets relating to AVTX-801 (D-galactose), AVTX-802 (D-mannose) and AVTX-803 (L-fucose) to AUG Therapeutics.

52

52

Benzinga

JUNE 20, 2023

DICE Therapeutics Inc (NASDAQ: DICE ) shares are trading higher Tuesday after Eli Lilly And Co (NYSE: LLY ) agreed to acquire the company. The Details: DICE Therapeutics and Eli Lilly announced a definitive agreement under which Eli Lilly will commence a tender offer to acquire all outstanding shares of DICE for $48 per.

52

52

Benzinga

JULY 7, 2022

Merck & Co Inc. NYSE: MRK ) is in advanced talks to acquire Seagen Inc. The FDA placed a clinical hold on DiaMedica Therapeutics Inc.'s Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus. Merck's Potential Buyout Of Seagen Expected Within Next Few Weeks.

98

98

Business Wire M&A

APRIL 27, 2023

BUSINESS WIRE)--Starton Therapeutics, Inc. Starton” or “the Company”), a clinical-stage biotechnology company focused on transforming standard-of-care therapies with proprietary continuous delivery technology, and Healthwell Acquisition Corp. . & WINNETKA, Ill.--(BUSINESS

Technology 98

Technology 98

Benzinga

JUNE 20, 2023

Eli Lilly And Co (NYSE: LLY ) has agreed to acquire DICE Therapeutics Inc (NASDAQ: DICE ), a biopharmaceutical company that leverages its proprietary DELSCAPE technology platform to develop oral therapeutic candidates for immunology indications.

Technology 52

Technology 52

Benzinga

FEBRUARY 13, 2024

Monday, Gilead Sciences Inc (NASDAQ: GILD ) agreed to acquire CymaBay Therapeutics Inc (NASDAQ: CBAY ) for $32.50 The company’s focus on a space where it has demonstrated commercial success is seen as a positive step to restore confidence in its growth prospects. per share in cash or a total equity value of $4.3

Equity 52

Equity 52

Law 360 M&A

MARCH 7, 2024

A shareholder of Harpoon Therapeutics Inc. sued in Delaware's Court of Chancery Thursday for corporate documents related to the company's proposed $680 million cash buyout by Merck, saying the proposed deal appears to unfairly "lock in a windfall for select Harpoon investors."

40

40

Law 360 M&A

MARCH 4, 2024

Creditors for drug developer Sorrento Therapeutics Inc. have asked a Texas bankruptcy judge to keep the company's Chapter 11 case in the Lone Star State, saying the U.S. trustee's bid to move it comes too late and wouldn't help those hoping for recoveries.

40

40

Benzinga

JUNE 22, 2023

Aeglea BioTherapeutics Inc (NASDAQ: AGLE ) has acquired Spyre Therapeutics , a privately-held biotechnology company focused on developing antibody therapeutics for inflammatory bowel disease.

Marketability 52

Marketability 52

Law 360 M&A

FEBRUARY 14, 2024

A Karuna Therapeutics Inc. shareholder has filed suit against the Boston-based biotechnology company alleging a proxy statement related to a proposed $14 billion buyout deal between Karuna and Bristol Myers Squibb contained false and misleading information and omitted key facts.

40

40

Benzinga

OCTOBER 2, 2023

02, 2023 (GLOBE NEWSWIRE) -- Klogenix LLC ("Klogenix" or "the Company") is pleased to announce that its intellectual property portfolio has been acquired by ADvantage Therapeutics, Inc. has been appointed Chief Science Officer at the acquiring company. ADvantage Therapeutics Inc. ADvantage Therapeutics, Inc.

45

45

Benzinga

SEPTEMBER 21, 2022

Sesen Bio Inc (NASDAQ: SESN ) and privately held Carisma Therapeutics Inc have entered into a merger agreement to combine the companies in an all-stock transaction.

Finance 52

Finance 52

Benzinga

APRIL 13, 2022

Halozyme Buys Specialty Product Company Antares In $960M Deal. Halozyme Therapeutics Inc (NASDAQ: HALO ) will acquire Antares Pharma Inc (NASDAQ: ATRS ) for $5.60 GlaxoSmithKline plc (NYSE: GSK ) has agreed to acquire Sierra Oncology Inc (NASDAQ: SRRA ) for $55 per share in cash, equivalent to an equity value of $1.9

Equity 98

Equity Technology 98

Benzinga

APRIL 26, 2023

Alzheimer's company Hoth Therapeutics Inc (NASDAQ: HOTH ) signed a Letter of Intent to merge with Algorithm Sciences Inc , a company focused on Pulmonary Arterial Hypertension (PAH). The combined company will be named Algorithm Sciences Inc.

52

52

Benzinga

JULY 19, 2023

Panbela Therapeutics Inc (NASDAQ: PBLA ) shares are trading higher after the company divested certain assets in its eflornithine pediatric neuroblastoma program to US WorldMeds 1 (USWM), a Kentucky-based specialty pharmaceutical company. Under the terms of the agreement, Panbela is entitled to receive up to approximately.

52

52

Benzinga

SEPTEMBER 1, 2022

Novo Nordisk A/S (NYSE: NVO ) has agreed to acquire Forma Therapeutics Holdings Inc (NASDAQ: FMTX ) for $20 per share in cash, representing a total equity value of $1.1 The deal value offers a premium of 92% to Forma Therapeutics' volume-weighted average price per share over the past 30 days.

Equity 52

Equity 52

Law 360 M&A

MAY 16, 2023

biotechnology company Amgen Inc.'s billion purchase of Ireland-based drugmaker Horizon Therapeutics PLC, filing a lawsuit in federal court to block the transaction. The Federal Trade Commission on Tuesday sought to shut down U.S. s proposed $27.8

52

52